Published in Eur J Nucl Med Mol Imaging on November 16, 2006
Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging (2008) 1.12
Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer. Eur Radiol (2008) 0.90
Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging (2009) 0.89
18F-FDG PET/CT evaluation of patients with ovarian carcinoma. Nucl Med Commun (2008) 0.88
[(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. Eur J Nucl Med Mol Imaging (2014) 0.88
Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management? Eur J Nucl Med Mol Imaging (2010) 0.86
Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging (2010) 0.85
Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence. Eur J Nucl Med Mol Imaging (2010) 0.84
Imaging of endometrial and cervical cancer. Insights Imaging (2010) 0.83
Positron emission tomography alone, positron emission tomography-computed tomography and computed tomography in diagnosing recurrent cervical carcinoma: a systematic review and meta-analysis. Arch Med Sci (2014) 0.76
Role of 18F-FDG PET/CT in the carcinoma of the uterus: a review of literature. Yonsei Med J (2014) 0.75
The role of FDG-PET/CT in gynaecological cancers. Cancer Imaging (2012) 0.75
Detection of recurrence by 18F-FDG PET in patients with endometrial cancer showing no evidence of disease. J Korean Med Sci (2010) 0.75
Complementary Roles of Squamous Cell Carcinoma Antigen and (18)F-FDG PET/CT in Suspected Recurrence of Cervical Squamous Cell Cancer. J Cancer (2015) 0.75
FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet (2000) 5.33
Cervical cancer. Lancet (2003) 4.05
Clinical applications of PET in oncology. Radiology (2004) 3.44
Endometrial carcinoma. N Engl J Med (1996) 3.31
Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med (2003) 2.88
Integrated PET/CT: current applications and future directions. Radiology (2006) 2.72
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol (2000) 2.28
Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol (2001) 1.59
Unknown primary tumors: detection with dual-modality PET/CT--initial experience. Radiology (2004) 1.48
Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol (2000) 1.41
Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology (2004) 1.36
Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. AJR Am J Roentgenol (2000) 1.18
Statistical methods for the estimation of sensitivity and specificity of site-specific diagnostic tests. J Periodontal Res (1997) 1.17
Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med (2003) 1.16
Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol (2003) 1.08
The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med (2002) 1.08
Evaluation of FDG PET in patients with cervical cancer. J Nucl Med (1999) 1.08
Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology (2004) 1.07
Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology (1996) 1.06
A combined PET/CT scanner: the choices. J Nucl Med (2001) 1.05
Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol (2004) 1.04
18F-FDG PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging (2005) 1.04
Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: value of dynamic contrast-enhanced subtraction MR imaging. Radiology (1997) 1.01
Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma. Gynecol Oncol (1998) 0.99
Tumor recurrence versus fibrosis in the female pelvis: differentiation with MR imaging at 1.5 T. Radiology (1988) 0.97
Initial experience with oral contrast in PET/CT: phantom and clinical studies. J Nucl Med (2003) 0.96
Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res (2001) 0.91
Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys (2003) 0.91
Cervical carcinoma: determination of recurrent tumor extent versus radiation changes with MR imaging. Radiology (1995) 0.89
The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies. Gynecol Oncol (2004) 0.88
Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med (2003) 0.85
Pelvic lesions in patients with treated cervical carcinoma: efficacy of pharmacokinetic analysis of dynamic MR images in distinguishing recurrent tumors from benign conditions. AJR Am J Roentgenol (1996) 0.85
The clinical application of serum squamous cell carcinoma antigen level monitoring in invasive cervical carcinoma. Gynecol Oncol (2002) 0.85
Computed tomography in endometrial carcinoma. Obstet Gynecol (2000) 0.85
A critical evaluation of current protocols for the follow-up of women treated for gynecological malignancies: a pilot study. Int J Gynecol Cancer (2001) 0.83
Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging (2002) 0.82
Dynamic MR imaging of recurrent postoperative cervical cancer. J Magn Reson Imaging (1996) 0.80
Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol (1997) 0.80
18F-FDG PET imaging in posttherapy monitoring of cervical cancers: from diagnosis to prognosis. J Nucl Med (2004) 0.79
Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. Radiology (2003) 0.77
Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med (2009) 8.20
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science (2013) 5.64
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst (2005) 3.64
Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet (2003) 2.95
Listening to action-related sentences activates fronto-parietal motor circuits. J Cogn Neurosci (2005) 2.66
Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol (2002) 2.27
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol (2011) 2.21
Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol (2008) 2.07
Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study. Int J Radiat Oncol Biol Phys (2013) 2.04
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer (2010) 2.03
Lungs of patients with acute respiratory distress syndrome show diffuse inflammation in normally aerated regions: a [18F]-fluoro-2-deoxy-D-glucose PET/CT study. Crit Care Med (2009) 1.99
[(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging (2008) 1.96
Positron detection for the intraoperative localisation of cancer deposits. Eur J Nucl Med Mol Imaging (2007) 1.95
When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol (2009) 1.90
Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med (2005) 1.85
Lung regional metabolic activity and gas volume changes induced by tidal ventilation in patients with acute lung injury. Am J Respir Crit Care Med (2011) 1.84
Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol (2005) 1.82
Carotid plaque echolucency increases the risk of stroke in carotid stenting: the Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) study. Circulation (2004) 1.82
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res (2005) 1.80
Crizotinib in anaplastic large-cell lymphoma. N Engl J Med (2011) 1.79
Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun (2007) 1.72
Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med (2007) 1.71
[11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging (2011) 1.67
Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging (2009) 1.66
Association between serum values of C-reactive protein and cytokine production in whole blood of patients with type 2 diabetes. Clin Sci (Lond) (2007) 1.63
Delivery delay with neoadjuvant chemotherapy for cervical cancer patients during pregnancy: a series of nine cases and literature review. Gynecol Oncol (2012) 1.63
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol (2010) 1.62
Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol (2009) 1.62
Fluorodeoxyglucose uptake measured by positron emission tomography and standardized uptake value predicts long-term survival of CT screening detected lung cancer in heavy smokers. J Thorac Oncol (2009) 1.61
The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol (2010) 1.61
The role of age of acquisition and language usage in early, high-proficient bilinguals: an fMRI study during verbal fluency. Hum Brain Mapp (2003) 1.60
Improved extraction of vegetable oils under high-intensity ultrasound and/or microwaves. Ultrason Sonochem (2007) 1.59
A modified damped Richardson-Lucy algorithm to reduce isotropic background effects in spherical deconvolution. Neuroimage (2009) 1.59
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol (2013) 1.58
Are borderline tumors of the ovary safely treated by laparoscopy? Gynecol Oncol (2004) 1.52
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst (2014) 1.46
Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Int J Cancer (2012) 1.45
A model-based deconvolution approach to solve fiber crossing in diffusion-weighted MR imaging. IEEE Trans Biomed Eng (2007) 1.44
PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res (2005) 1.43
High prevalence of (99m)tc-tetrofosmin reverse perfusion pattern in patients with myocardial infarction and angiographically smooth coronary arteries. Int J Cardiovasc Imaging (2002) 1.41
Autologous purified peripheral blood stem cell transplantation compare to chemotherapy in childhood acute lymphoblastic leukemia after low-risk relapse. Pediatr Blood Cancer (2011) 1.39
Estrogen receptor activation protects against TNF-α-induced endothelial dysfunction. Angiology (2013) 1.39
Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood (2010) 1.37
Positron emission tomography for radiation treatment planning. Strahlenther Onkol (2005) 1.33
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer (2012) 1.30
Performance evaluation of the new whole-body PET/CT scanner: Discovery ST. Eur J Nucl Med Mol Imaging (2004) 1.28
Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia. Neuroimage (2003) 1.23
Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology (2005) 1.22
Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. Int J Radiat Oncol Biol Phys (2008) 1.21
A database of [(11)C]WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage (2002) 1.20
Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy. Radiother Oncol (2006) 1.18
Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain (2006) 1.18
Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann Neurol (2005) 1.17
Inflammatory pseudotumor of mediastinum treated with tomotherapy and monitored with FDG-PET/CT: case report and literature review. Tumori (2010) 1.13
Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases. Gynecol Oncol (2009) 1.10
In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage (2008) 1.08
Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology (2004) 1.07
Respiratory gated PET/CT in a European multicentre retrospective study: added diagnostic value in detection and characterization of lung lesions. Eur J Nucl Med Mol Imaging (2012) 1.06